OSRHW — OSR Health, Inc.

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1840425 ·
Last close
Market Cap
52W High
52W Low
ADV30
Next earnings
OSR Health, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Europe, and Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis. In addition, the company distributes neurovascular intervention medical device and systems. The company was formerly known as OSR Holdings, Inc. and changed its name to OSR Health, Inc. in June 2026. OSR Health, Inc. was incorporated in 2020 and is based in Bellevue, Washington.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 484,057 160,281 -3,667,184 -2,931,461 172,187,773 1,566,701 44,796,654
Dec 2025 381,269 129,704 -6,385,534 -4,822,904 171,238,248 1,700,273 44,200,845
Sep 2025 627,747 261,734 -3,803,465 -2,126,595 177,289,528 2,177,309 43,131,683
Jun 2025 1,135,517 32,782 -5,229,178 331,414 185,415,021 1,584,406 46,261,975

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-5,265,922
Investing CF
$-3,816,904
Financing CF
$9,160,892
CapEx
$-173,704
Dividends Paid
Buybacks
EPS Diluted TTM
As of
2026-08-16

Balance + Analyst (yfinance extras)

Retained Earnings
$-40,101,342
Inventory
$462,455
Receivables
$526,259
ST Investments
$0
EBIT TTM
$-20,894,013
Pretax Income TTM
$-21,415,035
Interest Exp TTM
$521,022
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,808,743
EBITDA
$-7,419,085
Free Cash Flow
$-2,679,485
Enterprise Value
Total Cash
$1,499,603
Total Debt
$5,462,785
Shares Out
Trailing EPS
Book Value
$3.12
ROE
-11.3%
ROA
-6.0%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 2,905,805 -18,336,003 -18,010,899 171,238,248 44,200,845 -4,328,034
Dec 2024 3,530,303 -11,692,197 -10,328,910 175,239,579 32,031,363 -1,849,474
Dec 2023 0 -1,830,700 403,780 36,627,733 4,108,272 -818,766
Dec 2022 0 -621,316 1,064,967 120,757,699 21,659,379 -516,309

Peers — same industry

TickerNameMarket CapLastDaily %
ISRG INTUITIVE SURGICAL INC $133.84B $373.57
SYK STRYKER CORP $125.74B $327.81
MDT Medtronic plc $118.91B $92.90
MMM 3M CO $92.32B $179.01
BSX BOSTON SCIENTIFIC CORP $71.03B $49.01

News headlines (Yahoo Finance, 1h cache)

OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission
2026-08-21 15:45 · Yahoo
Sector Update: Healthcare Stocks Fall Thursday Afternoon
2026-08-20 17:43 · Yahoo
OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal
2026-08-19 19:45 · Yahoo
OSR Health Sees Global Shareholder Momentum at Critical Inflection Point
2026-08-19 10:30 · Yahoo
OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development
2026-08-11 12:52 · Yahoo
OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program
2026-08-07 19:00 · Yahoo
Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform
2026-08-03 13:02 · Yahoo
OSR Health Secures Nasdaq Communication: Loyalty CVR Program Will Not Trigger a Price Adjustment
2026-07-31 16:00 · Yahoo
OSR Health, A Message From the CEO
2026-07-13 16:37 · Yahoo
CORRECTION FROM SOURCE: Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target
2026-07-02 17:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.